62 related articles for article (PubMed ID: 38577301)
1. SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice.
Thrailkill KM; Clay Bunn R; Nyman JS; Rettiganti MR; Cockrell GE; Wahl EC; Uppuganti S; Lumpkin CK; Fowlkes JL
Bone; 2016 Jan; 82():101-7. PubMed ID: 26211996
[TBL] [Abstract][Full Text] [Related]
2. The effect of canagliflozin on gut microbiota and metabolites in type 2 diabetic mice.
Zeng L; Ma J; Wei T; Wang H; Yang G; Han C; Zhu T; Tian H; Zhang M
Genes Genomics; 2024 May; 46(5):541-555. PubMed ID: 38483772
[TBL] [Abstract][Full Text] [Related]
3. Author Correction: Anti-diabetic drug canagliflozin hinders skeletal muscle regeneration in mice.
Lv XH; Cong XX; Nan JL; Lu XM; Zhu QL; Shen J; Wang BB; Wang ZT; Zhou RY; Chen WA; Su L; Chen X; Li ZZ; Lin YN
Acta Pharmacol Sin; 2024 Jun; ():. PubMed ID: 38937577
[No Abstract] [Full Text] [Related]
4. Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia.
Chen PY; Gao WY; Liou JW; Lin CY; Wu MJ; Yen JH
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298929
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia.
Ruscica M; Zimetti F; Adorni MP; Sirtori CR; Lupo MG; Ferri N
Pharmacol Res; 2020 Mar; 153():104653. PubMed ID: 31931117
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Canagliflozin on High-Density Lipoprotein Cholesterol and Angiopoietin-Like Protein 3 in Type 2 Diabetes Mellitus.
Liu S; Ke J; Feng X; Wang Z; Wang X; Yang L; Zhao D
J Diabetes Res; 2024; 2024():2431441. PubMed ID: 38577301
[TBL] [Abstract][Full Text] [Related]
7. ANGPTL3 is a novel HDL component that regulates HDL function.
Yang L; Wang Y; Xu Y; Li K; Yin R; Zhang L; Wang D; Wei L; Lang J; Cheng Y; Wang L; Ke J; Zhao D
J Transl Med; 2024 Mar; 22(1):263. PubMed ID: 38462608
[TBL] [Abstract][Full Text] [Related]
8. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol.
Xu YX; Redon V; Yu H; Querbes W; Pirruccello J; Liebow A; Deik A; Trindade K; Wang X; Musunuru K; Clish CB; Cowan C; Fizgerald K; Rader D; Kathiresan S
Atherosclerosis; 2018 Jan; 268():196-206. PubMed ID: 29183623
[TBL] [Abstract][Full Text] [Related]
9. Streptozotocin-Treated High Fat Fed Mice: A New Type 2 Diabetes Model Used to Study Canagliflozin-Induced Alterations in Lipids and Lipoproteins.
Yu T; Sungelo MJ; Goldberg IJ; Wang H; Eckel RH
Horm Metab Res; 2017 May; 49(5):400-406. PubMed ID: 28395380
[TBL] [Abstract][Full Text] [Related]
10. Different relationship between ANGPTL3 and HDL components in female non-diabetic subjects and type-2 diabetic patients.
Zhao D; Yang LY; Wang XH; Yuan SS; Yu CG; Wang ZW; Lang JN; Feng YM
Cardiovasc Diabetol; 2016 Sep; 15(1):132. PubMed ID: 27620179
[TBL] [Abstract][Full Text] [Related]
11. Differential association of plasma angiopoietin-like proteins 3 and 4 with lipid and metabolic traits.
Mehta N; Qamar A; Qu L; Qasim AN; Mehta NN; Reilly MP; Rader DJ
Arterioscler Thromb Vasc Biol; 2014 May; 34(5):1057-63. PubMed ID: 24626437
[TBL] [Abstract][Full Text] [Related]
12. The Mechanism of Sodium-Glucose Cotransporter-2 Inhibitors in Reducing Uric Acid in Type 2 Diabetes Mellitus.
Dong M; Chen H; Wen S; Yuan Y; Yang L; Xu D; Zhou L
Diabetes Metab Syndr Obes; 2023; 16():437-445. PubMed ID: 36820272
[TBL] [Abstract][Full Text] [Related]
13. The Neuronal and Non-Neuronal Pathways of Sodium-Glucose Cotransporter-2 Inhibitor on Body Weight-Loss and Insulin Resistance.
Dong M; Chen H; Wen S; Yuan Y; Yang L; Li Y; Yuan X; Xu D; Zhou L
Diabetes Metab Syndr Obes; 2023; 16():425-435. PubMed ID: 36820270
[TBL] [Abstract][Full Text] [Related]
14. ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases.
Luo F; Das A; Khetarpal SA; Fang Z; Zelniker TA; Rosenson RS; Qamar A
Trends Cardiovasc Med; 2024 May; 34(4):215-222. PubMed ID: 36746257
[TBL] [Abstract][Full Text] [Related]
15. Effect of sodium-glucose cotransporter protein-2 inhibitors on left ventricular hypertrophy in patients with type 2 diabetes: A systematic review and meta-analysis.
Wang Y; Zhong Y; Zhang Z; Yang S; Zhang Q; Chu B; Hu X
Front Endocrinol (Lausanne); 2022; 13():1088820. PubMed ID: 36699027
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
